Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReabold Resources Regulatory News (RBD)

Share Price Information for Reabold Resources (RBD)

Share Price is delayed by 15 minutes
Get Live Data
83.50    -0.50 (-0.60%)
Bid:
82.00
Ask:
85.00
Spread: 3.00 (3.659%)
Market Cap: £12.11m
RBD Live PriceLast checked at - London Stock Exchange

Intraday Reabold Resources Share Chart

Acquisition

6 Feb 2007 07:00

Adventis Group PLC06 February 2007 For release at 07.00 Feb 6th 2007 ADVENTIS GROUP PLC ACQUISITION OF LEAPFROG MEDICAL COMMUNICATIONS LTD Adventis Group plc ( "Adventis" or the "Company", ticker ATG), the specialistmultimedia and marketing group, is pleased to announce that it has acquiredLeapFrog Medical Communications Limited ("LeapFrog"), a leading medicaleducation company, for a total maximum consideration of £2.65 million. The total consideration will be satisfied by the payment of initialconsideration of £1.306 million, payable as to £0.874 million in cash and £0.432million by the issue of 975,169 new ordinary shares in Adventis ("New OrdinaryShares"), and by deferred consideration of £0.72 million payable in tranches of£0.24 million on each of the first, second and third anniversaries of theacquisition. Each deferred consideration tranche will be satisfied as to 60 percent in cash and as to 40 per cent payable in new ordinary shares in Adventis.There is further deferred consideration payable of up to £0.624 million, basedon the achievement of certain profit growth related criteria over the followingthree years to be satisfied annually according to performance as to 50 per centin cash and 50 per cent payable in new ordinary shares in Adventis. LeapFrog, whose clients include, GSK, Pfizer, MSD, Roche and Novartis, wasestablished in 2001. It provides a range of medical education programmes to thehealthcare industry, promotional aids for sales representatives and alsoinitiates PR campaigns aimed at healthcare professionals and consumers forimproving clients' product brand awareness. For the year ended 30 November 2006,LeapFrog reported audited turnover of approximately £1.57 million and pre-taxprofit of approximately £0.39 million. Net assets at that date amounted toapproximately £0.25 million. Tim Schofield and Gail Rowe, LeapFrog's principaldirectors, will remain with the company following the acquisition. The acquisition will create one of the industry's top three pharmaceuticalindustry service providers, becoming part of an enlarged Healthcare servicesdivision embracing Affiniti Advertising, acquired in 2005, and RoundhouseHealthAd, acquired in 2006. The addition of LeapFrog to Affiniti and Roundhouse creates a formidable,award-winning team in the Adventis Healthcare division, with over 50 employeesworking in centralised premises in the Thames Valley. The enlarged Healthcareservices operations, whose other clients include Boehringer Ingelheim, Allergan,Baxter and Merck Serono, will have the capability to provide a complete range ofintegrated marketing services, from medical education, to advertising to newmedia. It will also provide the opportunity for an increased level ofcross-selling and the ability to provide multinational clients with a greaterlocal understanding of target markets service. Application has been made for the admission to AIM of the New Ordinary Shares,which will rank pari passu with the Company's existing issued ordinary shares,and dealings are expected to commence on 9th February 2007. Charles Phillpot, CEO, Adventis Group, said: "We will now be one of the fewcompanies in the industry to offer a full service marketing capability and theability to handle larger and more complex campaigns for clients. We are nowamong the top three players in two of our three chosen market sectors." Tim Schofield and Gail Rowe said: "We see joining forces with the two topcreative agencies in our industry as a unique way of adding value to ourclients. Being able to address their various needs within one group will be atremendous bonus for us all." ENDS Enquiries: Adventis Group Plc Charles Phillpot, CEO 020 7034 4750 Peter Linnell, Finance Director & Company Secretary 020 7034 4795 Adventis Financial PR Chris Steele 020 7034 4759 Peter Binns 020 7034 4760 Editor's Note: Adventis Group plc, provides a complete range of communications services,including corporate identity programmes, advertising campaigns, media andplanning and buying, literature, public relations, packaging, exhibitions,research and planning, interiors signage and digital media. The group employs145 staff in London and the southeast. Adventis has two other divisions focusing on providing a range of services tothe property and financial sectors. Adventis Group was admitted to AIM in 2004,mainly operating as a media and marketing services provider to the propertysector. LeapFrog becomes the group's ninth operating company. www.adventis.co.uk This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
15th Mar 20237:00 amRNSStatement regarding recent speculation
28th Feb 20233:35 pmRNSResult of General Meeting
16th Feb 20237:00 amRNSCompetent Person's Report on UK Licence P2478
14th Feb 20237:00 amRNSAppointment of Broker
10th Feb 20237:00 amRNSPosting of Circular and Notice of General Meeting
3rd Jan 20237:00 amRNSCompletion of the Acquisition of Simwell Resources
21st Nov 20223:37 pmRNSDirector/PDMR Dealings
17th Nov 20222:15 pmRNSResult of Requisitioned General Meeting
7th Nov 20227:00 amRNSISS Supports the Board of Reabold
4th Nov 20226:22 pmRNSResponse to Presentation from Requisitioners
2nd Nov 20227:00 amRNSInvestor Presentation
1st Nov 20221:15 pmRNSCompletion of the Sale of Corallian to Shell
31st Oct 20229:08 amRNSPosting of Circular and Notice of Requisitioned GM
31st Oct 20227:00 amRNSPosting of Circular and Notice of Requisitioned GM
20th Oct 20227:00 amRNSRequisition of General Meeting
17th Oct 20221:00 pmRNSPurported Requisition of General Meeting
5th Oct 20223:30 pmRNSSPA for Sale of Corallian to Shell for £32 million
30th Sep 20227:00 amRNSUnaudited HY Results for 6 months ended 30/06/22
29th Sep 20227:02 amRNSPublication of PEDL183 CPR by RPS Energy
28th Sep 20227:00 amRNSConditional Acquisition of Simwell Resources
23rd Sep 20227:00 amRNSWest Newton Community Update on Planned Activity
23rd Sep 20227:00 amRNSWest Newton Community Update on Planned Activity
15th Sep 20227:00 amRNSAcquisition of North Sea Assets from Corallian
14th Sep 20227:00 amRNSAgreed Terms of Conditional Sale of Corallian
9th Sep 20224:40 pmRNSSecond Price Monitoring Extn
9th Sep 20224:35 pmRNSPrice Monitoring Extension
9th Sep 20227:00 amRNSResponse to Governmental Energy Plan
1st Sep 20227:00 amRNSUpdate on Corallian and acquisition of licences
14th Jul 20221:56 pmRNSHolding(s) in Company
1st Jul 20227:00 amRNSBoard Change
29th Jun 20224:31 pmRNSResults of Annual General Meeting
23rd Jun 20227:00 amRNSInvestor Presentation
21st Jun 20227:00 amRNSWest Newton Conceptual Development Plan
7th Jun 202211:53 amRNSNotice of AGM – correction of typographical error
1st Jun 202210:06 amRNSNotice of Annual General Meeting
27th May 20227:00 amRNSFull Year Results for the year ended 31 Dec 2021
26th May 20227:00 amRNSCompletion of Equity Exchange Agreement
24th May 20227:00 amRNSReabold North Sea – Presentation on New Licences
23rd May 20227:00 amRNSShareholder Approval Received for Equity Exchange
13th May 20227:00 amRNSAppointment of Chief Financial Officer
4th May 20227:00 amRNSOffer for Corallian and acquisition of licences
3rd May 20227:00 amRNSUpdate on Equity Exchange with Daybreak Oil & Gas
17th Mar 202212:21 pmRNSPlanning Application Approval for Next Phase
25th Feb 20227:00 amRNSInvestor Presentation
25th Feb 20227:00 amRNSUpdate on Equity Exchange with Daybreak Oil & Gas
24th Feb 20224:42 pmRNSSecond Price Monitoring Extn
24th Feb 20224:37 pmRNSPrice Monitoring Extension
17th Feb 202212:38 pmRNSAmendment of Existing Option Terms
25th Jan 20229:05 amRNSSecond Price Monitoring Extn
25th Jan 20229:00 amRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.